Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes
Br J Clin Pharmacol
.
2015 Nov;80(5):929-31.
doi: 10.1111/bcp.12690.
Authors
Jennifer H Martin
1
2
,
Elizabeth Phillips
3
4
,
David Thomas
5
6
,
Andrew A Somogyi
7
8
Affiliations
1
School of Medicine and Public Health, University of Newcastle, New South Wales, Australia.
2
The University of Queensland Diamantina Institute, 37 Kent St, Woollongabba Queensland.
3
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
4
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western, Australia.
5
Garvan Institute of Medical Research, The Kinghorn Cancer Centre, 370 Victoria Street, Darlinghurst, NSW, 2010.
6
St Vincent's Clinical School, Faculty of Medicine, University of New South Wales.
7
Discipline of Pharmacology, Faculty of Health Sciences, University of Adelaide, Adelaide, 5001.
8
Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, Australia.
PMID:
26507561
PMCID:
PMC4631165
DOI:
10.1111/bcp.12690
No abstract available
Publication types
Editorial
MeSH terms
Humans
Neoplasms / drug therapy*
Neoplasms / genetics*
Precision Medicine / standards*